To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Gilead Sciences is experiencing mixed results in its product sales, with a notable decline in Veklury sales impacting overall performance, while HIV treatment sales, particularly Biktarvy, show positive growth [6][7][8]. Sales Performance - Gilead's total product sales reached $7.35 billion, slightly below the expected $7.43 billion, marking a decline of over 2% year-over-year [6]. - Veklury, Gilead's COVID treatment, saw a significant drop in sales by 60% to $277 million, missing the $333 million estimate due to lower hospitalization rates [7]. - Excluding Veklury, product sales increased by 4% to $7.1 billion, aligning with analysts' forecasts [7]. HIV Treatment Insights - Biktarvy generated $3.69 billion in sales, surpassing the forecast of $3.67 billion, and accounting for approximately half of Gilead's total product sales, with a year-over-year increase of 6% [8]. - Overall sales from Gilead's HIV treatment franchise rose 4% to $5.28 billion, including $701 million from Descovy, which grew nearly 20% [9]. Yeztugo Performance - Yeztugo, Gilead's newly approved HIV prevention shot, generated $39 million in sales during Q3, exceeding sell-side expectations of $35 million but falling short of buy-side forecasts of $40 million to $45 million [2]. - Gilead achieved 75% insurance coverage for Yeztugo in the U.S. ahead of schedule, with about 80% of patients having $0 co-pays [3]. Guidance and Future Outlook - Gilead raised the low end of its 2025 product sales outlook to $27.4 billion to $28.7 billion, which aligns with analysts' consensus of $28.71 billion [12]. - The company also increased its full-year earnings guidance to a range of $8.05 to $8.25 per share, surpassing the analysts' expectation of $8.04 [12].

Core Insights - Cosmos Health Inc. has initiated a new research and development program utilizing nanotechnology to enhance the effectiveness of phytochemical constituents in dietary supplements [1][2] - The new initiative builds on the proprietary technology developed during the creation of CCX Hydrogel, focusing on plant-based extract-loaded phytosomes to improve absorption, stability, and bioactivity of phytochemicals [2][5] - The company emphasizes a sustainable, solvent-free process for creating phytosomes, aligning with its commitment to environmentally responsible practices [3][5] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures a range of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [6]

Yes, as always, I'll start with a quote , but today it's from "A Farewell to Arms," by my favorite writer, Ernest Hemingway.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commi ...

Yes, as always, I'll start with a quote , but today it's from "A Farewell to Arms," by my favorite writer, Ernest Hemingway.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commi ...

Core Insights - Spherix Global Insights has launched its Market Dynamix™ service focusing on PD-1 Inhibition in Solid Tumors, providing analysis and advisory services for the immuno-oncology landscape as new PD-1 biosimilars and subcutaneous formulations approach market entry [1][2] Study Focus and Methodology - The 2025 edition of Market Dynamix™ will integrate quantitative insights from 100 U.S.-based oncologists, assessing current treatment algorithms and future expectations regarding the PD-1 inhibitor class [3] - The study will evaluate the impact of biosimilars and subcutaneous delivery formats on manufacturers, providers, and payers, delivering actionable intelligence for commercial planning and competitive positioning [3] - In 2026, the tracking will expand with RealTime Dynamix™: PD-1 Inhibition in Solid Tumors, providing quarterly updates on prescriber perceptions and competitive dynamics [3] Market Dynamics - The study will explore oncologist familiarity and perceived clinical equivalence of biosimilar PD-1 inhibitors, as well as adoption intent and expected impacts on practice economics and patient access [6] - It will also assess attitudes toward subcutaneous PD-1 formulations, focusing on convenience and anticipated shifts in site-of-care dynamics [6] - The analysis will include forecasts for PD-1 brand positioning and market share over the next 12 months, along with the influence of biomarker testing on treatment selection [6]

Two developments Thursday–Eli Lilly’s strong quarterly performance and Novo Nordisk’s unsolicited $9 billion bid for a startup–show why drugmakers can’t get enough of weight loss https://t.co/MpVV3xS7ei ...

Core Insights - The market for obesity and diabetes treatments is experiencing significant growth, generating billions in sales for Eli Lilly and leading to increased competition among drugmakers [1] Industry Overview - The obesity and diabetes treatment market is described as "scorching hot," indicating a high demand and lucrative opportunities for companies involved in this sector [1] - The competitive landscape is intensifying, as evidenced by a bidding war for another drugmaker, highlighting the strategic importance of this market segment [1] Company Focus - Eli Lilly is a key player in the obesity and diabetes treatment market, benefiting from substantial sales figures that contribute to its financial performance [1]

Core Insights - Metsera Inc. (NASDAQ:MTSR) has reached an all-time high due to a bidding war between Pfizer Inc. and Novo Nordisk, with Metsera's stock price increasing by 22.06% to $63.73 after hitting a 52-week high of $66.10 [1][2] Group 1: Bidding War Details - Novo Nordisk has made an $8.5 billion offer for Metsera, which is 16% higher than Pfizer's $7.3 billion offer, despite Pfizer having secured Metsera's approval for the merger previously [2] - Pfizer is preparing to sue both Metsera and Novo Nordisk, claiming that the acquisition attempt violates their agreement and antitrust laws [3] Group 2: Company Background and Market Context - Metsera is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and cardiometabolic diseases, positioning itself in the growing weight-loss drug market [5] - Pfizer had previously halted a clinical trial for its weight loss treatment, danuglipron, due to concerns over potential drug-induced liver failure [4]

Key Takeaways Insmed posted a Q3 loss of $1.75 per share, missing estimates despite higher revenue.Brinsupri added $28.1M in its first quarter of sales, driving strong investor optimism.Revenue rose 52% to $142.3M on growth in Arikayce and the successful Brinsupri launch.Insmed (INSM) reported a third-quarter 2025 loss of $1.75 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.32. In the year-ago quarter, the company posted a loss of $1.27 per share.Quarterly revenues rose 52% yea ...